Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT

Aswin Anand PAI, MSc, John C Panetta, PhD, Ezhil Pavai Mohanan, PhD, Raveen Stephen Stallon Illangeswaran, MSc, Balaji Balakrishnan, PhD, Eunice Sindhuvi Edison, PhD, Kavitha M Lakshmi, MSc, Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Fouzia N., Anu Korula, MD DM, Aby Abraham, MD DM, Biju George, MDDM, Vikram Mathews, MD DM, Alok Srivastava, MD,FRACP,FRCPA, Poonkuzhali Balasubramanian, PhD

Blood (2019) 134 (Supplement_1): 1977.

https://doi.org/10.1182/blood-2019-125604

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Kathryn S. Kolibaba, MD, Jose Azar, MD, Rama Balaraman, MD, Roger M. Lyons, MD, Mitchell R. Smith, MD PhD, Esteban Abella-Dominicis, MD, Wei Ye, PhD, Wen Shi, MD PhD, Thomas Giever, DO, Andres Forero-Torres, MD

Blood (2017) 130 (Supplement 1): 832.

https://doi.org/10.1182/blood.V130.Suppl_1.832.832

Published: 2017

Journal Articles

Targeting Chronic Myeloid Leukemia Stem Cells through Pharmacological Inhibition of HIF-1α

Giulia Cheloni, PhD, Michele Tanturli, PhD, DeSouza Ho Ngoc, Yi Shan, MD, Ignazia Tusa, PhD, Elisabetta Rovida, PhD, Shaoguang Li, MD PhD, Persio Dello Sbarba, MD PhD

Blood (2016) 128 (22): 4235.

https://doi.org/10.1182/blood.V128.22.4235.4235

Published: 2016

Journal Articles

Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant Therapy Without Causing Severe Hemorrhagic Events

Naoki Kurita, MD, PhD, Masanori Seki, MD, PhD, Yasuhisa Yokoyama, MD, PhD, Mamiko Sakata-Yanagimoto, MD, PhD, Naoshi Obara, MD, PhD, Kazumi Suzukawa, MD, PhD, Yuichi Hasegawa, MD, PhD, Shigeru Chiba, MD, PhD

Blood (2013) 122 (21): 2381.

https://doi.org/10.1182/blood.V122.21.2381.2381

Published: 2013

Journal Articles

PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Karen A. Urtishak, PhD, Wang Li-San, PhD, David T. Teachey, MD, Tasian K. Sarah, MD, Jeffrey S. Barrett, PhD, I-Ming L. Chen, Susan R. Atlas, PhD, Richard C. Harvey, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Stephen P. Hunger, MD, Cheryl L. Willman, MD, Carolyn A. Felix, MD

Blood (2013) 122 (21): 1669.

https://doi.org/10.1182/blood.V122.21.1669.1669

Published: 2013

Journal Articles

Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT

Arnon Nagler, MD, MSc, Myriam Labopin, MD, Avichai Shimoni, MD, Dietrich Beelen, Slawomira Kyrcz-Krzemien, MD, Kerstin Schufer-Eckart, Liisa Volin, Michael Hallek, Laimonas Griskevicius, Igor-Wolfgang Blau, Jochen Casper, Fabio Ciceri, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 545.

https://doi.org/10.1182/blood.V122.21.545.545

Published: 2013

Journal Articles

Role of PDGF/PDGFR in Regulation of Thrombopoiesis: A Possible Explanation for Imatinib Mesylate-Induced Thrombocytopenia in the Treatment of CML

Mo Yang, M.D.Ph.D, Fanyi Meng, MD, Jie yu Ye, Yue Xu, Bin Xiao, Beng Chong, MBBS, PhD

Blood (2012) 120 (21): 3348.

https://doi.org/10.1182/blood.V120.21.3348.3348

Published: 2012

Journal Articles

A Long Acting Polymeric Iron Chelator for the Treatment of Transfusion Associated Iron Overload

Jasmine La Juanie Hamilton, PhD Candidate, Muhammad Imran ul-haq, PhD, Benjamin Lai, MSc, Jayachandran N. Kizhakkedathu, PhD

Blood (2012) 120 (21): 486.

https://doi.org/10.1182/blood.V120.21.486.486

Published: 2012

Journal Articles

Abolished Daily Expression Patterns of SIRT1 , SIRT2 , and SIRT5 in Human Chronic Myeloid Leukemia

Ming-Yu Yang, PhD, Pai-Mei Lin, PhD, Jui-Feng Hsu, MD, Wen-Chi Yang, MD, Yi-Chang Liu, MD, Hui-Hua Hsiao, MD, Chao-Sung Chang, MD, Cheng-Ming Hsu, MD, Sheng-Fung Lin, MD

Blood (2012) 120 (21): 4613.

https://doi.org/10.1182/blood.V120.21.4613.4613

Published: 2012

Journal Articles

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E. Fayad, Michelle Fanale, Jorge Romaguera, Anas Younes

Blood (2012) 119 (9): 2171–2172.

https://doi.org/10.1182/blood-2011-11-391037

Published: 2012

Journal Articles

A Recombinant Thrombomodulin Improves Haemostatic Disturbance and Inflammation in Setpic Patients with DIC

Noritaka Yada, MD, Kenji Nishio, MD, PhD, Hidetada Fukushima, MD, Tadahiko Seki, MD, Yasuyuki Urizono, MD, Michiaki Hata, MD, Hideki Asai, MD, Masaaki Doi, MD, Hideto Matsui, MD, PhD, Mitsuhiko Sugimoto, MD, PhD, Kazuo Okuchi, MD, PhD

Blood (2011) 118 (21): 2293.

https://doi.org/10.1182/blood.V118.21.2293.2293

Published: 2011

Journal Articles

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Taiichi Kyo, M.D., Takeshi Okatani, M.D., Kouhei Kyo, M.D., Mitsuhiro Itagaki, M.D., Ryouta Imanaka, M.D., Koji Iwato, M.D., Hidkeki Asaoku, M.D., Yuuta Katayama, M.D.

Blood (2011) 118 (21): 3604.

https://doi.org/10.1182/blood.V118.21.3604.3604

Published: 2011

Journal Articles

Imatinib Mesylate Directly Impairs Class Switch Recombination through Downregulation of AID: Its Potential Efficacy as An AID Suppressor.

Toyotaka Kawamata, MD, Ai Kotani, MD, PhD, Takae Toyoshima, Kazuaki Yokoyama, MD, Arinobu Tojo, MD, PhD

Blood (2010) 116 (21): 3424.

https://doi.org/10.1182/blood.V116.21.3424.3424

Published: 2010

Journal Articles

Regulation of Genes of the Circadian Clock In Human Chronic Myeloid Leukemia: Abolished Daily Oscillation of PER1 , PER2 , PER3 and CRY2.

Ming-Yu Yang, PhD, Wen-Chi Yang, MD, Pai-Mei Lin, PhD, Jui-Feng Hsu, MD, Hui-Hua Hsiao, MD, Yi-Chang Liu, MD, Hui-Jen Tsai, MD, Chao-Sung Chang, MD, Sheng-Fung Lin, MD

Blood (2010) 116 (21): 3633.

https://doi.org/10.1182/blood.V116.21.3633.3633

Published: 2010

Journal Articles

Impaired Hydroxylation of 5-Methylcytosine In TET2 mutated Patients with Myeloid Malignancies

Anna Jankowska, Myunggon Ko, Yun Huang (equal contribution), Utz J. Pape, Hadrian Szpurka, Mamta Tahiliani, Hozefa S. Bandukwala, Jungeun An, Edward D. Lamperti, Kian Peng Koh, X. Shirley Liu, L. Aravind, Suneet Agarwal, Anjana Rao, PhD, Jaroslaw P Maciejewski, MD, PhD, FACP

Blood (2010) 116 (21): 1.

https://doi.org/10.1182/blood.V116.21.1.1

Published: 2010

Journal Articles

Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients.

Ajoy K. Samanta, Ph.D., Bastianella Perazzona, Ph.D., Sandip N. Chakraborty, Xiaoping Sun, MD, PhD, Hardik Modi, Ravi Bhatia, MD, Ralph B. Arlinghaus, PhD

Blood (2010) 116 (21): 1220.

https://doi.org/10.1182/blood.V116.21.1220.1220

Published: 2010

Journal Articles

Intracerebellar Granulocytic Sarcoma Presenting as a First Manifestation of Relapse in Chronic Myelogenous Leukemia (CML) During Imatinib Mesylate Therapy: A Case Report and Literature Review.

Agustin Pimentel, MD, Daniel A Forman, DO, Sharon L Swierczynski, MD, PhD, Anthony A Donato, MD, Brian Le, MD

Blood (2009) 114 (22): 4289.

https://doi.org/10.1182/blood.V114.22.4289.4289

Published: 2009

Journal Articles

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Susan M. O'Brien, David F. Claxton, Michael Crump, Stefan Faderl, Thomas Kipps, Michael J. Keating, Jean Viallet, Bruce D. Cheson

Blood (2009) 113 (2): 299–305.

https://doi.org/10.1182/blood-2008-02-137943

Published: 2009

NARROW

Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Targeting Chronic Myeloid Leukemia Stem Cells through Pharmacological Inhibition of HIF-1α

Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant Therapy Without Causing Severe Hemorrhagic Events

PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT

Role of PDGF/PDGFR in Regulation of Thrombopoiesis: A Possible Explanation for Imatinib Mesylate-Induced Thrombocytopenia in the Treatment of CML

A Long Acting Polymeric Iron Chelator for the Treatment of Transfusion Associated Iron Overload

Abolished Daily Expression Patterns of SIRT1 , SIRT2 , and SIRT5 in Human Chronic Myeloid Leukemia

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

A Recombinant Thrombomodulin Improves Haemostatic Disturbance and Inflammation in Setpic Patients with DIC

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Imatinib Mesylate Directly Impairs Class Switch Recombination through Downregulation of AID: Its Potential Efficacy as An AID Suppressor.

Regulation of Genes of the Circadian Clock In Human Chronic Myeloid Leukemia: Abolished Daily Oscillation of PER1 , PER2 , PER3 and CRY2.

Impaired Hydroxylation of 5-Methylcytosine In TET2 mutated Patients with Myeloid Malignancies

Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients.

Intracerebellar Granulocytic Sarcoma Presenting as a First Manifestation of Relapse in Chronic Myelogenous Leukemia (CML) During Imatinib Mesylate Therapy: A Case Report and Literature Review.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only